ETFDH and liver cancer: Building on established metformin‐ hepatic cancer causality, MR analysis of drug targets (Table S8) revealed non‐significant causal effects via IVW: PRKAB (OR = 0.819, 95% CI 0.661–1.016, p = 0.070), ETFDH (OR = 1.085, 95% CI 0.952–1.236, p = 0.223), and GPD1L (OR = 1.022, 95% CI 0.904–1.155, p = 0.725), potentially due to limited statistical power (Figure 4).